Quick filters:
Open Data
Open Code
Pre-registered
Funding Declared
COI Declared
Open Access
Clear Filters
Characterizing epigenetic aging in an adult sickle cell disease cohort.
Blood Adv
(Unknown)
Published: 2024
Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.
Shotton R; Broadbent R; Alchawaf A; Mohamed MB; Gibb A; Martinez-Calle N; Fox CP; Bishton M; Pender A; Gleeson M; Cunningham D; Davies A; Yadollahi S; Eyre TA; Collins G; Djebbari F; Kassam S; Garland P; Watts E; Osborne W; Townsend W; Pocock R; Ahearne MJ; Miall F; Wang X; Linton KM.
Blood Adv
(Unknown)
Published: 2024
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Brudno JN; Natrakul DA; Karrs J; Patel N; Maass-Moreno R; Ahlman MA; Mikkilineni L; Mann J; Stroncek DF; Highfill SL; Fromm GC; Patel R; Pittaluga S; Kochenderfer JN.
Blood Adv
(Unknown)
Published: 2024
A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis.
Shree T; Haebe S; Czerwinski DK; Eckhert E; Day G; Sathe A; Grimes S; Frank MJ; Maeda LS; Alizadeh AA; Advani R; Hoppe RT; Long SR; Martin B; Ozawa MG; Khodadoust MS; Ji HP; Levy R.
Blood Adv
(Unknown)
Published: 2024
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Hirayama AV; Kimble EL; Wright JH; Fiorenza S; Gauthier J; Voutsinas JM; Wu Q; Yeung CCS; Gazeau N; Pender BS; Kirchmeier DR; Torkelson A; Chutnik AN; Cassaday RD; Chapuis AG; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ.
Blood Adv
(Unknown)
Published: 2024
Clinical, immunological features, treatments, and outcomes of autoimmune hemolytic anemia in patients with RAG deficien…
Wang C; Sun B; Wu K; Farmer JR; Ujhazi B; Geier CB; Gordon S; Westermann-Clark E; Savic S; Secord E; Sargur R; Chen K; Jin JJ; Dutmer CM; Kanariou MG; Adeli M; Palma P; Bonfim C; Lycopoulou E; Wolska-Kusnierz B; Dbaibo G; Bleesing J; Moshous D; Neven B; Schuetz C; Geha RS; Notarangelo LD; Miano M; Buchbinder DK; Csomos K; Wang W; Wang JY; Wang X; Walter JE.
Blood Adv
(Unknown)
Published: 2024
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AM…
Cai SF; Huang Y; Lance JR; Mao HC; Dunbar AJ; McNulty SN; Druley T; Li Y; Baer MR; Stock W; Kovacsovics T; Blum WG; Schiller GJ; Olin RL; Foran JM; Litzow M; Lin T; Patel P; Foster MC; Boyiadzis M; Collins RH; Chervin J; Shoben A; Vergilio JA; Heerema NA; Rosenberg L; Chen TL; Yocum AO; Druggan F; Marcus S; Stefanos M; Druker BJ; Mims AS; Borate U; Burd A; Byrd JC; Levine RL; Stein EM.
Blood Adv
(Unknown)
Published: 2024
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
Hamadani M; Spira A; Zhou X; Liao L; Chen L; Radford J; Ai W; Solh M; Ardeshna KM; Hess B; Caimi PF; Stathis A; Carlo-Stella C; Alderuccio JP; Kahl B; Wang Y; Qin Y; Xu ZC; Zinzani PL.
Blood Adv
(Unknown)
Published: 2024
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leuk…
Hill BT; Ma S; Zent CS; Baran AM; Wallace DS; Advani A; Winter A; Winter J; Gordan L; Karmali R; Liesveld JL; Mulford DA; Rowland C; Bui A; Sportelli P; Miskin HP; Weiss MS; Friedberg JW; Barr PM.
Blood Adv
(Unknown)
Published: 2024
Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R.
Blood Adv
(Unknown)
Published: 2024
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Shah UA; Moshier E; Derkach A; Huang Y; Mailankody S; Tan CR; Maclachlan K; Hultcrantz M; Korde N; Hassoun H; Thibaud S; Sanchez L; Rodriguez C; Richard S; Richter J; Rossi A; Cho HJ; Lesokhin A; Chari A; Usmani SZ; Jagannath S; Parekh S; Gallagher EJ.
Blood Adv
(Unknown)
Published: 2024
Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 …
Bader P; Pötschger U; Dalle JH; Moser LM; Balduzzi A; Ansari M; Buechner J; Güngör T; Ifversen M; Krivan G; Pichler H; Renard M; Staciuk R; Sedlacek P; Stein J; Heusel JR; Truong T; Wachowiak J; Yesilipek A; Locatelli F; Peters C.
Blood Adv
(Unknown)
Published: 2024
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia.
Tamburini J; Mouche S; Larrue C; Duployez N; Bidet A; Salotti A; Hirsch P; Rigolot L; Carras S; Templé M; Favale F; Flandrin-Gresta P; Le Bris Y; Alary AS; Mauvieux L; Tondeur S; Delabesse E; Delhommeau F; Sujobert P; Kosmider O.
Blood Adv
(Unknown)
Published: 2023
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress.
Gomez Solsona B; Horn H; Schmitt A; Xu W; Bucher P; Heinrich A; Kalmbach S; Kreienkamp N; Franke M; Wimmers F; Schuhknecht L; Rosenwald A; Zampieri M; Ott G; Lenz G; Schulze-Osthoff K; Hailfinger S.
Blood Adv
(Unknown)
Published: 2023
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.
Jian Y; Chang L; Shi MX; Sun Y; Chu XX; Xue H; Huang WR; Shen XL; Ma J; Jia GR; Feng YQ; Xi ZF; Zhao YH; Ma YP; Xiao J; Ma GY; Wang QM; Bao L; Dong YJ; Zhou HB; Sun CY; Su GH; Yan Y; Qimuge SY; Su LP; Sun JN; Tian WW; Sun XL; Ing HM; Gao D; Chen WM; Li J; Gao W.
Blood Adv
(Unknown)
Published: 2023